FRAZIER KENNETH C 4

What Happened
Kenneth C. Frazier, a director of Eikon Therapeutics, purchased 111,111 shares in an open-market transaction on February 4, 2026. The shares were acquired at $18.00 each for a total consideration of $1,999,998. This was a straight purchase (transaction code P), which is generally viewed as a more informative insider action than routine sales.

Key Details

• Transaction date: 2026-02-04; filing date: 2026-02-06 (filed within the typical 2-business-day window).
• Price and size: 111,111 shares at $18.00 per share; total value $1,999,998.
• Transaction type: Open market purchase (code P).
• Shares owned after transaction: Not specified in the excerpt of the Form 4 provided.
• No 10b5-1 plan, tax-withholding, or other special footnotes were disclosed in the provided transaction summary.

Context

• Purchases by directors can signal personal investment in the company, but they do not prove future performance—this is factual reporting of the insider's buy.
• This transaction is a direct purchase of common stock, not an option exercise, gift, or award.